Source: 4-traders

BlackThorn: BlackThorn Therapeutics : Announces R&D Updates

(marketscreener.com) BTRX-335140 Poised to Enter Phase 2 Efficacy Studies and BTRX-323511 to Enter IND-enabling Studies Company Increasing Investment in Computational Psychiatry (CompPsych) Platform for Targeted CNS Therapeutics and Deprioritizing BTRX-246040 to Focus on Proprietary Programs BlackThorn...http://www.marketscreener.com/news/BlackThorn-Therapeutics-Announces-R-D-Updates--27824415/?utm_medium=RSS&utm_content=20190104

Read full article »
BlackThorn's Competitors | BlackThorn's News | BlackThorn's Financials
Stay up-to-date with the latest news on BlackThorn
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
William J Martin's photo - President & CEO of BlackThorn

President & CEO

William J Martin

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on BlackThorn